5. Thomas CJ, Limper AH. Pneumocystis pneumonia. N Engl J Med, 2004, 350:2487-2498.
[2]
6. Obeid KM, Aguilar J, Szpunar S, et al. Risk factors for pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk, 2012, 12:66-69.
[3]
7. Chang H, Yeh HC, Su YC, et al. Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab. Chin Med Assoc, 2008, 71:579-582.
[4]
8. Tsimberidou AM, Younes A, Romaguera J, et al. Immunosuppression and infectious complications in patients with stage Ⅳ indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer, 2005, 104:345-353.
[5]
9. Martin-Garrido I, Carmona EM, Specks U, et al. Pneumocystis pneumonia in patients treated with rituximab. Chest, 2013, 144:258-265.
[6]
10. Jiang X, Mei X, Feng D, et al. Prophylaxis and treatment of pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy:a systemic review and meta-analysis. PLoS One, 2015, 10:e0122171.
[7]
11. Lund FE, Hollifield M, Schuer K, et al. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol, 2006, 176:6147-6154.
[8]
12. Church DL, Ambasta A, Wilmer A, et al. Development and validation of a Pneumocystis jirovecii real-time polymerase chain reaction assay for diagnosis of Pneumocystis pneumonia.Can J Infect Dis Med Microbiol, 2015, 26:263-267.
[9]
13. Azoulay E, Berqeron A, Chevret S, et al. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest, 2009, 135:655-661.
[10]
14. Matsumura Y, Shindo Y, Linuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC infect Dis, 2011, 11:76.
[11]
15. William BM, Bonqu NR, Bast M, et al. The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev Bras Hematol Hemotre, 2013, 35:189-191.
[12]
16. Vogel M, Weissgerber P, Goeppert B, et al. Accuracy of serum LDH elevation for the diagnosis of Pneumocystis jiroveci pneumonia. Swiss Med Wkly, 2011, 141:w13184.
18. Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement:treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med, 2011, 183:96-128.
[15]
19. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis, 2011, 5:41-59.
[16]
20. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome:associated illness and prior corticosteroid therapy. Mayo Clin Proc, 1996, 71:5-13.
[17]
21. Belhz K, Kramm CM, Laws HJ, et al. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin Padiatr, 2006, 218:177-179.
[18]
22. Festic E, Gajic O, Limper AH, et al. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection:outcome and associated features. Chest, 2005, 128:573-579.
[19]
23. Bienvenu AL, Traore K, Plekhanova I, et al. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis, 2016, 46:11-17.
2. Monnet X, Vidal-Petiot E, Osman D, et al. Critical care management and outcome of severe pneumocystis pneumonia in patients with and without HIV infection. Crit Care, 2008, 12:R28.
[22]
3. Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med, 2014, 127:1242.e11-e17.
